Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market
Attention deficit hyperactivity disorder also known as hyperkinetic disorder/ neuropsychiatric disorder is one of the most common brain disorder characterized by symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (<12 years age) as compared to older population. The exact cause of the Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be resulted due to improper functioning of the nervous system that led to inattentiveness and hyperactivity/impulsiveness condition. The treatment includes different modalities such as medication, psychotherapy, and education/training.
The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) market is growing due to changing in lifestyle and systems impacting the quality of the births. Compromised children'™s diet with preservatives, increased cases of ADHD in children, increasing awareness among patients and physicians about ADHD treatment are expected to further grow the Attention deficit hyperactivity disorder (ADHD) market. However, the presence of comorbid conditions in children leads to underdiagnoses of ADHD treatment, lack of availability of non-stimulant drugs, stringent regulatory guidelines, and a high cost of the medication are expected to hamper the growth of the ADHD market.
The global Attention deficit hyperactivity treatment disorder (ADHD) market is divided into following categories-
- Medication type
- Stimulants
- Amphetamines
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Age group
- Pediatric
- Adolescent
- Adults
- End-users
Pharmacies such hospital, retail, online pharmacies and specialty clinics.
And lastly on the basis of geographical regions, the global ADHD market has five major regions- North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America holds the largest share in global ADHD treatment market due to rising prevalence of ADHD, increase in healthcare expenditure, ongoing clinical trials, and an early approval of drugs in the U.S., favorable insurance policies and technological advancement for the treatment will fuel the Attention deficit hyperactivity treatment disorder (ADHD) market. Europe accounts for the significant share due to increase in the population, rising prevalence of ADHD patients, and increased R & D for the innovation of new products in Attention deficit hyperactivity disorder (ADHD) market. Asia-Pacific holds a dominant share in attention deficit hyperactivity disorder therapeutics market owing to developing healthcare infrastructure, government initiatives, etc.
Some of the key players in the global attention deficit hyperactivity treatment disorder (ADHD) market are Neos Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Supernus Pharmaceuticals, Inc. (U.S.),Shire plc (Ireland), MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.) and Actavis (U.S.) to name a few. In 2017, Shire Plc received U.S. FDA approval for a long-acting attention-deficit drug Adderall XR aimed at adolescents and adults.
The global Attention deficit hyperactivity disorder therapeutics market is in budding stage, several local and international players are actively involved in the growth of the market. Launching of new products, collaborations, acquisitions and mergers, and agreements are some of the key strategies followed by various companies to increase the attention deficit hyperactivity treatment disorder (ADHD) market share.